Last updated on May 2019

A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis


Brief description of study

This Phase 2 study is designed to evaluate the efficacy and safety of itacitinib in men and women with moderate to severe UC. The study consists of Part A and Part B, which consist of 12 weeks of double-blind, randomized, placebo-controlled treatment periods followed by 40 weeks open label extension period.

Clinical Study Identifier: TX220945

Find a site near you

Start Over

Advanced Pharma CR, LLC

Located in: Miami, FL United States
  Connect »

Remington-Davis, Inc. Clinical Research

Located in: Columbus, OH United States
  Connect »

LENUS Research

Located in: Sweetwater, FL United States
  Connect »

Advanced Research Institute, Inc

Located in: New Pt Richey, FL United States
  Connect »

eStudySite - Chula Vista

Located in: Chula Vista, CA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.